Top Story Today
One Surgery, No Implant: Regeneron Lands Its First Gene Therapy Approval
Hundreds of babies are born each year in the U.S. unable to hear because of a mutation in the OTOF gene, which acts like a severed cable between the ear and the brain. Regeneron's newly approved Otarmeni fixes that cable with a single surgical infusion into the inner ear. In a 24-patient trial, 70% of evaluable children hit the key hearing endpoint, some going from profound deafness to picking up conversational speech. The FDA approved it just 61 days after submission, a particularly swift review.
Why it matters: This isn't about revenue (the patient population is tiny). It's about a major antibody giant proving its genetics-first platform can deliver across entirely new therapeutic modalities, right when Pfizer is retreating from gene therapy.
Read more →Deals and Policy
Regeneron Was the Last Holdout. The White House Just Got Its Deal.
Regeneron became the 17th and final major drugmaker to sign the White House's Most Favored Nation pricing deal, covering 80% of the U.S. drug market. The terms include a 58% price cut on cholesterol drug Praluent, free access to its new gene therapy Otarmeni, and $27 billion in domestic manufacturing commitments. In return, Regeneron gets tariff relief.
Read more →Funding and Financings
Avalyn Pharma Wants $200M to Prove You've Been Taking Your Lung Drugs Wrong
Avalyn is pricing its IPO at $201M to $212M to fund inhaled versions of two blockbuster pulmonary fibrosis pills. The logic: delivering drugs directly to the lungs cuts systemic exposure by roughly 15x, which means fewer side effects and fewer patients quitting treatment. Nobody else is running late-stage trials with this approach, so if Phase 3 works, Avalyn would own the category.
Read more →Corporate Strategy and Leadership
Pfizer Bet Its Cancer Brand on a Rookie Quarterback
Pfizer tapped NFL Draft prospect Fernando Mendoza as the face of its cancer screening campaign, timed to ride draft-week viewership. It's not just a feel-good play: more screenings mean more early diagnoses, which fills the commercial funnel for a $43 billion oncology portfolio built on the Seagen acquisition. Only 50% of women get annual breast exams despite 99% survival rates with early detection.
Read more →Two Months and Out: Helus Pharma's CEO Shown the Door
Helus Pharma fired CEO Michael Cola just two months after hiring him, and the board isn't explaining why. The timing is brutal: Phase 3 data on a psychedelic-inspired depression treatment arrives in Q4, and the company now operates under interim leadership. Shares are down approximately 19% year-to-date.
Read more →